Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy

Ewing sarcoma is a rare and aggressive cancer of the bone and soft tissues that mainly affects children and young adults. Despite intensive multimodal therapy, the prognosis of patients with metastatic or recurrent disease remains poor. Therefore, novel therapeutic approaches are needed to improve the outcomes of patients with Ewing sarcoma. The disialoganglioside GD2 is highly expressed on Ewing sarcoma cells, making this tumor eligible for treatment with Dinutuximab beta, a monoclonal antibody targeting this antigen. Through in vitro and in vivo approaches, this study demonstrated that Dinutuximab beta effectively suppressed tumor growth by 60% (p=0.0135 vs vehicle) and improved survival rate by 68% (p=0.0006 vs vehicle) in a mouse model xenograft. The combination therapy with doxorubicin demonstrated superior efficacy compared to monotherapy, with enhanced tumor suppression (86%; p=0.0009 vs vehicle) and an extension of survival rate (146%; p=0.000025 vs vehicle). Overall, this study showed that Dinutuximab beta is effective against Ewing sarcoma, especially in combination with the standard induction chemotherapy regimen for this tumor. Integrating Dinutuximab beta into the standard chemotherapy regimen for Ewing sarcoma offers a promising new therapeutic approach that can potentially improve the prognosis for patients with high-risk disease, offering a more effective alternative to existing treatments. Overall design: Human Ewing Sarcoma derived cells were subcutaneously injected into athymic nude mice. Animals were treated with either vehicle or Dinutuximab beta for 5 conscutive days. At day 5 (T1) and 11 (T2) tumor were collected and analysed. 4 tumors for each experimental group were analysed.